Cholic acid

Name: Cholic acid
Brand: MedChemExpress
SKU: HY-N0324
Rating: 5.0 (20 reviews)

Cat. No.: HY-N0324 Purity: 99.80%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active.

For research use only. We do not sell to patients.

CAS No. : 81-25-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 20 publication(s) in Google Scholar

Other Forms of Cholic acid:

20 Publications Citing Use of MCE Cholic acid

In Vivo Efficacy Study

Histological Imaging/Staining

Bio/Physico-chemical Assay

RT-PCR

: Cholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719. [Abstract]; The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.

: Cholic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Sep 5:S2090-1232(24)00389-8. [Abstract]; The tumor-promoting effects of taurine could be reversed by bile acids (Cholic acid (245.25 mg/kg; p.o.; Once daily)) in C57 mice (n = 6).

: Cholic acid purchased from MedChemExpress. Usage Cited in: Aquaculture. 2023 Sep 18, 740123.; The results showed that dietary Cholic acid (CA, 100 mg/kg) supplementation increased the levels of T-CHO, LDL-C, and HDL-C (P < 0.05).

: Cholic acid purchased from MedChemExpress. Usage Cited in: Aquaculture. 2023 Sep 18, 740123.; Cholic acid (CA, 100 mg/kg; dietary administration) significantly increased the mRNA expression levels of IL-6, IL-8, IL-1β, and iNOS in grass carp.

: Cholic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Jul 22:10:854425.; HE results of the placental explant. NC Group: normal placenta; ICP group: normal placenta was stimulated for 48 h with 100 uM Cholic acid.

: Cholic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Jul 22:10:854425.; Western blotting results and gray histogram of the placental explant. NC group: normal placenta; ICP group: the normal placenta was stimulated for 48 h with 100 uM Cholic acid.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active^[1]^[2].

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
CHO	EC₅₀	13.6 μM Compound: 3, CA	Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay	[PMID: 17685603]
CHO	EC₅₀	13.6 μM Compound: 4, CA	Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay	[PMID: 20014870]
CHO	EC₅₀	13.6 μM Compound: 5, CA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
COS-1	EC₅₀	> 100 μM Compound: 4, CA	Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay	[PMID: 20014870]
GBM	IC₅₀	> 50 μM Compound: 1a, CA, cholic acid	Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HCT-116	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HCT-116	IC₅₀	> 50 μM Compound: 1a, CA, cholic acid	Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HEK-293T	EC₅₀	> 150 μM Compound: CA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	> 150 μM Compound: CA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK293	IC₅₀	5.3 μM Compound: 1, CA	Agonist activity at mouse TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level Agonist activity at mouse TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level	[PMID: 20801037]
HEK293	IC₅₀	6 μM Compound: 1, CA	Agonist activity at human TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level Agonist activity at human TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level	[PMID: 20801037]
HEK293	IC₅₀	> 1000 μM Compound: 25	Antiproliferative activity against HEK293 cells by MTT assay Antiproliferative activity against HEK293 cells by MTT assay	[PMID: 18805690]
HET-1A	CC₅₀	1075 μM Compound: 4, CA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-29	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
Huh-7	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
KMS-11	IC₅₀	> 50 μM Compound: 1a, CA, cholic acid	Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
LoVo	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
MCF7	IC₅₀	50 μM Compound: 25	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 18805690]
MGC-803	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
NCI-H716	EC₅₀	13.6 μM Compound: 1, CA	Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis	[PMID: 24900463]
RKO	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SK-HEP1	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SW480	IC₅₀	> 200 μM Compound: CA	Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]

In Vitro

Cholic acid (1 mg/mL, 30 min) competitively binds Na⁺/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cholic acid (1% (w/w) Cholic acid-supplemented diet; p.o.; 14 days) decreases SHP (small heterodimer partner) protein expression, potentially via the upregulation of miR142-3p. Cholic acid increases CYP2D6 expression and activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Tg-CYP2D6 adult male mice (8 weeks of age and weighing 20–25 g)^[2]
Dosage:	1% (w/w) Cholic acid-supplemented diet
Administration:	Oral, 14 days
Result:	Decreases SHP expression and increased CYP2D6 activity.

Clinical Trial

Molecular Weight

408.57

Formula

C₂₄H₄₀O₅

CAS No.

81-25-4

Appearance

Solid

Color

White to off-white

SMILES

C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C

Structure Classification

Steroids

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (122.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

0.1 M NaOH : 33.33 mg/mL (81.58 mM; ultrasonic and adjust pH to 9 with NaOH)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4476 mL	12.2378 mL	24.4756 mL
5 mM	0.4895 mL	2.4476 mL	4.8951 mL
10 mM	0.2448 mL	1.2238 mL	2.4476 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.80%

Select Batch:

Data Sheet (277 KB) SDS (392 KB)

COA (251 KB) HNMR (272 KB) RP-HPLC (236 KB)

Handling Instructions (2659 KB)

References

[1]. Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684. [Content Brief]

[2]. Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

0.1 M NaOH / DMSO	1 mM	2.4476 mL	12.2378 mL	24.4756 mL	61.1890 mL
	5 mM	0.4895 mL	2.4476 mL	4.8951 mL	12.2378 mL
	10 mM	0.2448 mL	1.2238 mL	2.4476 mL	6.1189 mL
	15 mM	0.1632 mL	0.8159 mL	1.6317 mL	4.0793 mL
	20 mM	0.1224 mL	0.6119 mL	1.2238 mL	3.0595 mL
	25 mM	0.0979 mL	0.4895 mL	0.9790 mL	2.4476 mL
	30 mM	0.0816 mL	0.4079 mL	0.8159 mL	2.0396 mL
	40 mM	0.0612 mL	0.3059 mL	0.6119 mL	1.5297 mL
	50 mM	0.0490 mL	0.2448 mL	0.4895 mL	1.2238 mL
	60 mM	0.0408 mL	0.2040 mL	0.4079 mL	1.0198 mL
	80 mM	0.0306 mL	0.1530 mL	0.3059 mL	0.7649 mL
DMSO	100 mM	0.0245 mL	0.1224 mL	0.2448 mL	0.6119 mL

Cholic acid Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cholic acid81-25-4Endogenous Metaboliteglycinetaurinecholesterol excretionHepG2Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cholic acid

Customer Review

Other Forms of Cholic acid:

Cholic acid Related Antibodies

20 Publications Citing Use of MCE Cholic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Cholic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cholic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report